Mydecine and Johns Hopkins plan a "seamless" (combined) Phase II/III clinical trial of MYCO-001 to treat nicotine addiction.
Ionic Brands (CSE: IONC) is creating a multi-state, consumer focused, premium cannabis porfolio consisting of iconic national brands.
They have:
- Stylish products
- World Class Management Team
- A proven and repeatable strategy for success
Experienced and proven luxury cannabis concentrates brand
One of the tops selling vape brands in WA State with a loyal customer base
Largest standalone oil manufacturer in the state of WA
Consistent sales growth over 3 years with a verified marketing blueprint
Offers investors exposure to a premium luxury cannabis brand
Demonstrated to have a winning formula to become the top vape company in WA
Massive growth opportunity available with expansion into OR, NV and CA
Mydecine and Johns Hopkins plan a "seamless" (combined) Phase II/III clinical trial of MYCO-001 to treat nicotine addiction.
Roughly 8 million people per year are dying preventable deaths because of lack of (legal) access to psychedelic medicine. It's also killing the economy.
Less than three years after the first licensed recreational marijuana retailers began doing business in Massachusetts, regulated cannabis dispensaries have rung up more than $2 billion in adult-use cannabis sales, state officials announced on Wednesday.
New York lawmakers approved two officials for the state’s adult-use cannabis program in a special session this week, WHAM reports.
The Washington State attorney general’s office appeared alongside lawyers representing cancer patients on Thursday, telling a federal appeals panel that people in end-of-life care deserve legal access to psilocybin under state and federal right-to-try laws.
In response to the Seattle City Council’s request for policy advice on how to curb overdose deaths, a local task force is recommending the widespread decriminalization of all drugs.